Terbinafine 250mg/5ml oral suspension
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Terbinafine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Terbinafine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Terbinafine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
250 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 19 · Randomised trials: 5 · 2001–2026
Showing the 50 most relevant studies, sorted by most relevant.
Aimoldina A, Smagulova A, Kukhar Y, et al.
2026
Song G, Xie W, She X, et al.
2026
- Trichophyton
- Tinea
- Antifungal Agents
BackgroundThe emergence of Trichophyton indotineae as a multidrug-resistant dermatophyte has challenged conventional therapeutic approaches for dermatophytosis, leading to a significant therapeutic dilemma. The absence of formal epidemiological cutoff values (ECVs) under the Clinical and Laboratory Standards Institute (CLSI) framework has led to inconsistent interpretation of antifungal susceptibility testing (AFST) data, highlighting the urgent need for standardised susceptibility interpretation criteria and effective therapeutic strategies.ObjectivesThis study aimed to (1) establish CLSI-based estimated tentative ECVs (ET-ECVs) to facilitate reliable minimum inhibitory concentration (MIC) interpretation; (2) analyse resistance rates of T. indotineae to terbinafine, itraconazole and voriconazole using a large-scale global dataset and (3) explore and identify effective therapeutic options following first-line treatment failure.MethodsThis systematic review compiled global susceptibility data for T. indotineae through comprehensive literature searches, including only studies that performed CLSI- or European Committee on Antimicrobial Susceptibility Testing (EUCAST)-standardised AFST. Furthermore, the clinical efficacy of voriconazole was specifically evaluated by summarising and analysing reported treatment cases.ResultsA total of 67 studies from 14 countries, comprising 981 isolates, were included. The proposed CLSI ET-ECVs for terbinafine, itraconazole and voriconazole were 0.125, 0.25 and 1 mg/L, respectively, showing full alignment with EUCAST tentative epidemiological cutoff values (TECOFFs). Integrated resistance rates were 77.6% for terbinafine, 17.0% for itraconazole and 1.4% for voriconazole. Cross-resistance analysis revealed that terbinafine resistance predominated, with 14.3% of isolates co-resistant to itraconazole. In vitro susceptibility data demonstrated high activity of voriconazole and clinical case summaries further confirmed its favourable therapeutic efficacy, with complete remission reported in all evaluated cases.ConclusionThis study defined the CLSI ET-ECVs for interpreting T. indotineae MICs, highlighted the resistance burden to first-line agents and provided in vitro evidence supporting further evaluation of voriconazole as a potential effective alternative therapy. These findings may provide critical warnings regarding the high-resistance landscape and help guide antifungal susceptibility interpretation for this emerging multidrug-resistant pathogen.
Abstract licence: CC BY
Kilbas I, Kahraman Kilbas EP, Ciftci IH, et al.
2026
Background/Objectives: In recent years, reports regarding terbinafine resistance in Trichophyton spp. have increased. The aim of this study is to evaluate the prevalence of terbinafine resistance in Trichophyton spp. species on a regional and species basis and to systematically analyze the antifungal susceptibility testing methods used and the available data. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA guideline. Studies published until 1 December 2025 were searched in the PubMed/MEDLINE, Scopus, Web of Science, and Embase databases. Studies reporting antifungal susceptibility test results using species-level identification, standardized, or study-defined methodologies were included. Pooled prevalence estimates were calculated with a random-effects model. Heterogeneity was evaluated with the I2 statistic. Subgroup analyses were performed according to publication period, resistance definition groups, species, and geographic region. SQLE mutation patterns were summarized descriptively. Results: Nineteen studies reported from 13 different countries were included in the meta-analysis. In sensitivity analyses that included surveillance-based studies, the combined prevalence rate was found to be 3.2% (95% confidence interval 1.5-6.7). Higher descriptive resistance levels were observed in T. indotineae and T. mentagrophytes, although species-related differences were not statistically significant. Among studies reporting SQLE mutations, alterations involving codons 393 and 397 were the most frequently described; however, mutation patterns were summarized descriptively because of methodological heterogeneity among studies. Conclusions:Trichophyton spp. terbinafine resistance is an emerging global threat. Standardized susceptibility testing, harmonized epidemiological cut-off values, and enhanced molecular surveillance are essential for accurate detection, resistance monitoring, and effective clinical management.
Abstract licence: CC BY
Ashutosh Kumar Singh, Aradhana Masih, A. Khurana, et al.
Mycoses, 2018
Tsuyoshi Yamada, M. Maeda, M. Alshahni, et al.
Antimicrobial Agents and Chemotherapy, 2017
R. Kano, Utako Kimura, M. Kakurai, et al.
Mycopathologia, 2020
Z. Yin, Jiali Xu, D. Luo
Journal of Dermatological Treatment, 2012
S. Singh, Najuma Subba, R. Tilak
Indian Journal of Dermatology, 2020
Bharti Gaba, Mohammad Fazil, S. Khan, et al.
Bulletin of Faculty of Pharmacy, Cairo University, 2015
P. Nenoff, S. Verma, A. Ebert, et al.
Journal of Fungi, 2020
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
69 found
Half-life
36 hours
Mechanism
Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epo…
Food interactions
2 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70%
[L9065]
…
Half-life
36 hours
[L9065]
…
Protein binding
99%
[A5538]
…
Volume of distribution
250mg
[A1279]
Metabolism
[A38984]
…
Elimination
80%
[A1279]
…
Clearance
250mg
[A1279]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
[L9065]
Terbinafine hydrochloride also treats yeast infections of the skin caused by Candida species and Malassezia furfur.
[L9068]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 960 interactions
[L10487]
The TDLO for women is 210mg/kg/6W.
[L10487]
Overdose data with terbinafine is rare, however symptoms are expected to be nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.
[L9065]
Treat overdose with activated charcoal as well as symptomatic and supportive therapy.
[L9068]
Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L9065]
Over the course of a week, 1% topical terbinafine's Cmax increases from 949-1049ng/cm2 and the AUC increases from 9694-13,492ng/cm2/h.
[A188168]
[L9065]
However, the terminal half life ranges from 200-400 hours as it distributes into skin and adipose tissue.
[L9065]
1% topical terbinafine's half life increases over the first seven days from approximately 10-40 hours.
[A188168]
[A5538]
[A1279]
[A38984]
1-naphthaldehyde is then oxidized to 1-naphthoic acid or reduced to 1-naphthalenemethanol.
[A38984]
Terbinafine can also be hydroxylated by CYP1A2, 2C9, 2C8, 2B6, and 2C19 to hydroxyterbinafine.
[A38984]
Hydroxyterbinafine is then oxidized to carboxyterbinafine or N-demethylated by CYP3A4, 2B6, 1A2, 2C9, 2C8, and 2C19 to desmethylhydroxyterbinafine.
[A38984]
Terbinafine can be N-demethylated to desmethylterbinafine.
[A38984]
Desmethylterbinafine is then dihydroxylated to a desmethyldihydrodiol or hydroxylated to desmethylhydroxyterbinafine.
[A38984]
Finally, terbinafine can be dihydroxylated to a dihydrodiol which is then N-demethylated to a desmethyldihydrodiol.
[A38984]
[A1279]
The unmetabolized parent drug is not present in urine.
[A188204]
[A1279]
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
Appears to function in modulating the activity of the immune system during the acute-phase reaction
ATC D01AE15
ATC D01BA02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Terbinafine
Additional database identifiers
Drugs Product Database (DPD)
11385
Drugs Product Database (DPD)
707
ChemSpider
1266005
BindingDB
50018518
ZINC
ZINC000001530981
UniProt Accession
ERG1_CANAL
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11279
GenAtlas
SQLE
GeneCards
SQLE
GenBank Gene Database
D78130
GenBank Protein Database
2443316
Guide to Pharmacology
2433
UniProt Accession
ERG1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9604
GenAtlas
PTGS1
GeneCards
PTGS1
GenBank Gene Database
M31822
GenBank Protein Database
387018
Guide to Pharmacology
1375
UniProt Accession
PGH1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8498
GenAtlas
ORM1
GeneCards
ORM1
GenBank Gene Database
X02544
GenBank Protein Database
757907
UniProt Accession
A1AG1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8499
GeneCards
ORM2
GenBank Gene Database
BC015964
GenBank Protein Database
16359000
UniProt Accession
A1AG2_HUMAN
UniProt Accession
MDR2_TRIIM
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72